A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer

Investigational New Drugs

Volumn 18, Issue 1, 2000, Pages 83-91

  Schwartsmann, Gilberto ^a,e   Schunemann, H ^a   Gorini, C N F ^a,b   Ferreira Filho, A F ^a   Garbino, C ^c   Sabini, G ^d   Muse, I ^d   DiLeone, L ^a   Mans, D R ^a  

^a S Amer Off Anticancer Drug Devmt   (Brazil)

^b HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^c Hospital Policial   (Uruguay)

^d HOSPITAL DE CLÍNICAS   (Uruguay)

^e HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cisplatin; Decitabine; Hypomethylating; Non small cell lung cancer; Phase I; Phase II

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CARBOPLATIN; CISPLATIN;

ADULT; ADVANCED CANCER; AGE; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG INFUSION; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; LUNG NON SMALL CELL CANCER; MALAISE; MALE; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REVIEW; SEX RATIO; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AZACITIDINE; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 0034106513     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006388031954     Document Type: Review

References (30)

1. Health Statistics: Mortality figures in 1994; City of Porto Alegre, State of Rio Grande do Sul, Secretariat for Health and Environment, Ministry of Health of Brazil, Vol 20, 1996
2. Hansen HH, Roth M: Lung Cancer. In Cancer Chemotherapy and Biological Response Modifiers Annual 12. HM Pinedo, DL Longo and BA Chabner, Eds. Elsevier Science Publishers BV: 449-459, 1991
3. Thatcher N, Ranson M, Lee SM et al.: Chemotherapy in non-small cell lung cancer. Annals of Oncology 6: 83-95, 1995
4. Comis RL, Friedland DM: New chemotherapy agents in the treatment of advanced non-small cell lung cancer. Lung Cancer 12: 63-69, 1995
5. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data in individual patients from 52 randomized clinical trials. Br Med J 311: 899-909, 1995
6. Souquet PJ, Chauvin F, Boissel JP et al.: Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 342: 19-21, 1993
7. Grill R, Oxman AD, Julian JA: Chemotherapy for advanced non-small cell lung cancer: how much is enough? J Clin Oncol 11: 1866-1872, 1993
8. Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JHL, Lohman PHM, Reedijk J: Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA. Formation, identification and quantitation. Biochemistry 24: 707-711, 1985
9. Reed E, Yuspa SH, Zwelling LA et al.: Quantitation of cis-diamminedichloroplatinum (II) (cisplatin)-DNA-intrastrands adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 77: 545-550, 1986
10. Momparler RL, Goodman J: In vitro cytotoxic and biochemical effects of 5-aza-2′-deoxycytidine. Cancer Res 37: 163-166, 1977
11. Lenzi R, Abbruzzese J, Hunt B, Jackson D, Frost P: Reversal of cisplatinum resistance by 5-aza-2′-aza-deoxycytidine (DAC) in human ovarian cell lines. Proc Am Assoc Cancer Res 33: 497, 1992 (Abstr #2865)
12. Frost P, Abbruzzese J, Hunt B, Lee D, Ellis M: Synergistic effect of cisplatinum in murine tumor cells pretreated with 2′-deoxy-5-azacytidine. In: 5-Aza-2′-deoxycytidine: Preclinical and clinical studies. Momparler RL, deVos D (eds), pp 29-34, PCH Publications, Haarlem, The Netherlands, 1990
13. Leyva A, Schwartsmann G, Boieje LMC et al.: Growth-inhibitory effects of 5-aza-2′-deoxycytidine in HL-60 promyelocytic leukemia cells resistant to differentiation induction. Biochem Biophys Res Commun 23: 595-597, 1987
14. Schwartsmann G, Pinedo HM, Leyva A: Resistance of HL-60 promyelocytic leukemia cells to induction of differentiation and its reversal by combination treatment. Eur J Cancer 23: 739-743, 1987
15. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP: 5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64: 922-929, 1984
16. Gonzalez-Zulueta M, Bender CM, Pao MM, Zingg JM, Tsai YC, Arap W: Activation of a silent p16/CDKN2 tumor suppressor gene by 5-aza-2′-deoxycytidine restores growth control to human cancer cells. Proc Am Assoc Cancer Res 37: 420, 1996 (Abstr 2868)
17. Willemze R, Richel DJ, Arentsen-Honders MW, Colly LP: Preliminary results of 5-aza-2′-deoxycytidine (DAC) in patients with resistant and relapsed acute leukemia. In: 5-aza-2′-deoxycytidine: preclinical and clinical studies. Momparler RL, deVos D (eds). PCH Publications, Haarlem, The Netherlands, pp 183-190, 1990
18. Chabot GG, Monparlet RL: Pharmacokinetics of 5-aza-2′-deoxycytidine in animals and man: relevance to clinical trials. In: 5-aza-2′-deoxycytidine: preclinical and clinical trials. PCH Publications, Haarlem, The Netherlands, pp 105-116, 1990
19. Van Groeningen CJ, Leyva A, O'Brien A, Boeije L, Gall HE, Pinedo HM: Phase I and pharmacokinetic study of 5-Aza-2′-deoxycytidine in cancer patients. Cancer Res 46: 4831-4826, 1986
20. Dodion PF, Clavel M, ten Bokkel Huinink W, Robinson E, Renard J, Cavalli F: Phase I-II trials with 5-aza-2′-deoxycytidine conducted by the Early Clinical Trials Group of the EORTC. In: 5-aza-2′-deoxycytidine. Preclinical and clinical trials. PCH Publications, Haarlem, The Netherlands, pp 117-124, 1990
21. Willemze R, Richel DJ, Arentsen-Honders W, Colly LP: Preliminary results of 5-Aza-2′-deoxycytidine in patients with the Ara-C resistant and sensitive acute leukemia. In: Momparler RL, de Vos D (eds), 5-Aza-2′-deoxycytidine, preclinical and clinical studies. PCH Publications, Haarlem, The Netherlands, pp. 183-191, 1990
22. Schwartsmann G, Fernandes MS, Schaan MD et al.: Decytabine plus daunorubicin as first line treatment in patients with acute myeloid leukemia: Preliminary observations. Leukemia (Suppl 1) 11: 28-31, 1997
23. Schwartsmann G, Wanders J, Koier IJ et al.: EORTC New Drug Development Office coordinating and monitoring program for phase I and II trials with new anticancer agents. Eur J Cancer 27: 1182-1168, 1991
24. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-349, 1961
25. Miller AB, Hoogstraten B, Staquet M et al.: Reporting results of cancer therapy treatment. Cancer 47: 207-214, 1981
26. Lilenbaum RC, Green MR: Novel chemotherapeutic agents in the treatment of non-small cell lung cancer. J Clin Oncol 11: 1391-1402, 1993
27. Rapp E, Pater JK, Wellan A et al.: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633-641, 1988
28. Crino L, Scagliotti G, Marangolo M et al.: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer. A phase II study. J Clin Oncol 15: 297-303, 1997
29. Johnson DH, Paul DM, Hande KR et al.: Paclitaxel plus carboplatin in the treatment of advanced non-small cell cancer; A phase II trial. J Clin Oncol 14: 2054-2060, 1996
30. Zalcberg J, Millward M, Bishop J et al.: Phase II study of docetaxel and cisplatin in advanced non-small cell lung cancer. J Clin Oncol 16: 1948-1953, 1998